Evaluation of the Visby medical COVID-19 point of care nucleic acid amplification test
Short communication
[키워드] acute respiratory syndrome
analytical sensitivity
calculated
Characteristics
CIconfidence interval
claimed
collected
Concordance
confidence interval
coronavirus
COVID-19
COVID-19 test
Cpcrossing point
Critical
crossing point
demonstrated
diagnostic
Emergency use authorization
EUA
EUAemergency use authorization
evaluated
experiment
FDAFood and Drug Administration
Food and Drug Administration
horseradish peroxidase
HRPhorseradish peroxidase
in viral
inactivated
institutional review board
IRBinstitutional review board
Laboratory
LIGHT
limit of detection
LoDlimit of detection
Mayo Clinic
NAATnucleic acid amplification test
nasopharyngeal
negative percent agreement
NPAnegative percent agreement
NPnasopharyngeal
nucleic acid amplification
nucleic acid amplification test
overall concordance
Patient
Patient care
platform
POC
POCpoint-of-care
point of care
point-of-care
positive
positive percent agreement
positive sample
PPApositive percent agreement
qualitative detection
Rapid
rapid SARS-CoV-2 testing
reducing
reference method
resulting
reverse transcription quantitative polymerase chain reaction
Roche
Roche Diagnostics
RT-qPCR
RT-qPCRreverse transcription quantitative polymerase chain reaction
SARS-CoV-2
SARS-CoV-2 nucleic acid
SARS-CoV-2severe acute respiratory syndrome coronavirus 2
serial dilution
severe acute respiratory syndrome coronavirus 2
specimen
Swab
TaqMan
Transmission
Transport media
viral transfer media
virus
Visby
VTM
VTMviral transfer media
was tested
WHOWorld Health Organization
widespread
World Health Organization
[DOI] 10.1016/j.clinbiochem.2021.11.007 [Article Type] Short communication
[DOI] 10.1016/j.clinbiochem.2021.11.007 [Article Type] Short communication